1.41
price up icon0.71%   0.01
after-market After Hours: 1.38 -0.03 -2.13%
loading
Clearmind Medicine Inc stock is traded at $1.41, with a volume of 73,476. It is up +0.71% in the last 24 hours and up +14.63% over the past month. Clearmind Medicine Inc is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements. The company's intellectual portfolio currently consists of four patent families. The company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.
See More
Previous Close:
$1.40
Open:
$1.43
24h Volume:
73,476
Relative Volume:
0.21
Market Cap:
$5.64M
Revenue:
-
Net Income/Loss:
$-6.78M
P/E Ratio:
-0.3946
EPS:
-3.5729
Net Cash Flow:
$-4.67M
1W Performance:
-4.08%
1M Performance:
+14.63%
6M Performance:
+18.49%
1Y Performance:
+914.39%
1-Day Range:
Value
$1.38
$1.45
1-Week Range:
Value
$1.33
$1.50
52-Week Range:
Value
$0.10
$6.80

Clearmind Medicine Inc Stock (CMND) Company Profile

Name
Name
Clearmind Medicine Inc
Name
Phone
-
Name
Address
-
Name
Employee
4
Name
Twitter
Name
Next Earnings Date
Name
Latest SEC Filings
Name
CMND's Discussions on Twitter

Clearmind Medicine Inc Stock (CMND) Latest News

pulisher
Oct 22, 2024

Clearmind Medicine (NASDAQ:CMND) Shares Down 12.3% – What’s Next? - Defense World

Oct 22, 2024
pulisher
Oct 11, 2024

Clearmind Medicine Inc [CMND] Revenue clocked in at $0.00 million, down -51.60% YTD: What’s Next? - The DBT News

Oct 11, 2024
pulisher
Oct 11, 2024

Clearmind advances trial for alcohol use disorder therapy - Investing.com

Oct 11, 2024
pulisher
Oct 11, 2024

Clearmind advances trial for alcohol use disorder therapy By Investing.com - Investing.com Australia

Oct 11, 2024
pulisher
Oct 10, 2024

Clearmind Medicine Inc (NASDAQ: CMND): Is Its Value Too High Compared To Others? - Stocks Register

Oct 10, 2024
pulisher
Oct 10, 2024

Clearmind Medicine Inc Inc. (CMND) Price Performance: A Technical Analysis Perspective - The InvestChronicle

Oct 10, 2024
pulisher
Oct 10, 2024

Examining CMND’s book value per share for the latest quarter - US Post News

Oct 10, 2024
pulisher
Oct 10, 2024

Clearmind Medicine Announces IRB Approval for FDA First-In-Human Clinical Trial of CMND-100 at Second Clinical Site - Marketscreener.com

Oct 10, 2024
pulisher
Oct 09, 2024

Rail Vision secures $20 million equity deal with Yorkville - Investing.com

Oct 09, 2024
pulisher
Oct 08, 2024

SciSparc gains as Clearmind partnership yields 3 new international patent applications - MSN

Oct 08, 2024
pulisher
Oct 01, 2024

Clearmind Medicine Completed Type A Meeting with the FDA - GlobeNewswire

Oct 01, 2024
pulisher
Sep 30, 2024

SciSparc Secures FDA Green Light to US Launch of its Pivotal Phase IIb Clinical Trial for Breakthrough Tourette Syndrome Treatment - Marketscreener.com

Sep 30, 2024
pulisher
Sep 26, 2024

Clearmind Medicine appoints new board member - Investing.com

Sep 26, 2024
pulisher
Sep 24, 2024

Clearmind, SciSparc slide amid weight-loss study results - MSN

Sep 24, 2024
pulisher
Sep 19, 2024

Could Psychedelics End Binge Drinking? A Breakthrough Patent Says Yes - MSN

Sep 19, 2024
pulisher
Sep 17, 2024

Clearmind Medicine patents new addiction treatment - Investing.com India

Sep 17, 2024
pulisher
Sep 16, 2024

SciSparc Unveils Breakthrough Ibogaine Therapy Patent - TipRanks

Sep 16, 2024
pulisher
Sep 16, 2024

Clearmind Medicine Announces the Notice of an International Patent Application for Pioneering - The Bakersfield Californian

Sep 16, 2024
pulisher
Sep 16, 2024

SciSparc-Clearmind Medicine Collaboration Announces the - GlobeNewswire

Sep 16, 2024
pulisher
Sep 16, 2024

SciSparc-Clearmind Medicine Collaboration Announces the Publication of an International Patent Application for Pioneering Ibogaine Combination Therapy - StockTitan

Sep 16, 2024
pulisher
Sep 14, 2024

Contrasting Clearmind Medicine (NASDAQ:CMND) and Phio Pharmaceuticals (NASDAQ:PHIO) - Defense World

Sep 14, 2024
pulisher
Sep 13, 2024

Clearmind Medicine files patent for PTSD treatment compounds - Investing.com

Sep 13, 2024
pulisher
Sep 12, 2024

Clearmind Medicine and Yissum File International Patent Application for Revolutionary Psychedelic Compounds for PTSD Treatment - Morningstar

Sep 12, 2024
pulisher
Sep 11, 2024

SciSparc shares up on patents filed for psychedelic compounds with Clearmind - MSN

Sep 11, 2024
pulisher
Sep 07, 2024

SciSparc and Clearmind Innovate Mental Health Treatment - TipRanks

Sep 07, 2024
pulisher
Sep 06, 2024

Clearmind Medicine files patent for novel MDMA therapy - Investing.com

Sep 06, 2024
pulisher
Sep 06, 2024

SciSparc-Clearmind Medicine Collaboration Leads to Publication of International Patent Application for Innovative MDMA-Based Combination Treatment - Yahoo Finance UK

Sep 06, 2024
pulisher
Sep 06, 2024

SciSparc-Clearmind Medicine Collaboration Leads to - GlobeNewswire

Sep 06, 2024
pulisher
Sep 06, 2024

SciSparc-Clearmind Medicine Collaboration Leads to Publication of International Patent ... - The Bakersfield Californian

Sep 06, 2024
pulisher
Sep 02, 2024

A History of Outperforming Analyst Forecasts and Beating the Odds: Clearmind Medicine Inc (CMND) - SETE News

Sep 02, 2024
pulisher
Sep 02, 2024

Financial Metrics Check: Clearmind Medicine Inc (CMND)’s Ratios for Trailing Twelve Months - The Dwinnex

Sep 02, 2024
pulisher
Aug 29, 2024

Clearmind and SciSparc file patent for ketamine-based therapy - Investing.com

Aug 29, 2024
pulisher
Aug 29, 2024

SciSparc and Clearmind Innovate in Mental Health Therapy - TipRanks

Aug 29, 2024
pulisher
Aug 29, 2024

Clearmind Medicine Announces Publication of its Patent Application for Innovative Ketamine-Based Combination Treatment - Morningstar

Aug 29, 2024
pulisher
Aug 26, 2024

Clearmind Biomedical Announces FDA Clearance and First U.S. Surgery of the Neuroblade System for Minimally Invasive Neurosurgery - PR Newswire

Aug 26, 2024
pulisher
Aug 25, 2024

Weekly Roundup on the Cannabis Sector & Psychedelic Sector - Market Exclusive

Aug 25, 2024
pulisher
Aug 23, 2024

CMND’s Market Quandary: Decoding the Ups and Downs of 2023 - The InvestChronicle

Aug 23, 2024
pulisher
Aug 22, 2024

Clearmind receives patent for drug to treat binge behavior - Green Market Report

Aug 22, 2024
pulisher
Aug 22, 2024

Clearmind Medicine Inc (CMND) Stock: Navigating Market Highs and Lows in 52 Weeks - The InvestChronicle

Aug 22, 2024
pulisher
Aug 21, 2024

Clearmind Medicine secures new US patent for binge behavior regulator - Investing.com India

Aug 21, 2024
pulisher
Aug 21, 2024

Clearmind Medicine Granted U.S. Patent Approval for Binge Behavior Treatment - Yahoo Finance

Aug 21, 2024
pulisher
Aug 20, 2024

Clearmind Medicine Inc (CMND) Clearly Signals Buy-Into the Stock: Don’t ignore the signals - SETE News

Aug 20, 2024
pulisher
Aug 19, 2024

Is CMND’s price to cash per share ratio a concern for investors? - US Post News

Aug 19, 2024
pulisher
Aug 19, 2024

Financial Metrics Unveiled: Clearmind Medicine Inc (CMND)’s Key Ratios in the Spotlight - The Dwinnex

Aug 19, 2024
pulisher
Aug 16, 2024

Thinking about buying stock in Brainstorm Cell Therapeutics, Cle - GuruFocus.com

Aug 16, 2024
pulisher
Aug 16, 2024

Clearmind, Yissum Apply for International Patent for Psychedelics - MarketWatch

Aug 16, 2024
pulisher
Aug 16, 2024

Clearmind Medicine and Yissum Expand Collaboration with International Patent Application for Generation 3.0 Psychedelic Compounds to Treat Mental Disorders - StockTitan

Aug 16, 2024
pulisher
Aug 10, 2024

Clearmind Medicine (NASDAQ:CMND) Stock Price Down 0.8% - Defense World

Aug 10, 2024
pulisher
Aug 09, 2024

Why Doximity Shares Are Trading Higher By Over 28%; Here Are 20 Stocks Moving Premarket - Benzinga

Aug 09, 2024
pulisher
Aug 09, 2024

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday - InvestorPlace

Aug 09, 2024
pulisher
Aug 07, 2024

Clearmind Medicine: New Scientific Publication Shows MEAI's Potential as a Novel Weight Loss Drug - EIN News

Aug 07, 2024

Clearmind Medicine Inc Stock (CMND) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$77.28
price up icon 2.02%
$20.39
price up icon 2.15%
$382.77
price up icon 1.58%
$53.29
price down icon 0.47%
$208.03
price up icon 0.38%
$110.97
price up icon 1.84%
Cap:     |  Volume (24h):